

Supplemental Figure - 1.



Experimental design and treatment schedule.

Telmisartan (high dose, 3 mg/kg/d; moderate dose, 0.66 mg/kg/d; low dose, 0.33 mg/kg/d) mixed in a high-fat diet was administered to 6-wk-old male C57BL/6J mice for 20 wk and then discontinued for 3 weeks. Mice on a telmisartan-free diet served as the control. The experimental time points for the high-dose group (**■**) moderate-dose group (**■**), low-dose group (**■**), and control group (**□**) are indicated (n = 5-10/time point). *¹, High-fat diet containing telmisartan. *², Telmisartan-free high-fat diet. *³, Weeks after treatment cessation. At each time point, mice were sacrificed 2 h after the injection of ¹⁸F-FDG to examine the following: (1) biodistribution of ¹⁸F-FDG, (2) plasma BUN and creatinine levels, and (3) ¹⁸F-FDG excretion by autoradiography of kidney sections.

Supplemental Figure- 2.



📕 High-dose group 📕 Moderate-dose group 📕 Low-dose group 🔲 Control group

Sequential measurement of BUN, creatinine, and blood ¹⁸F-FDG levels.

Six-wk-old male C57BL/6J mice were given telmisartan (high dose, 3 mg/kg/d; moderate dose, 0.66 mg/kg/d; low dose: 0.33 mg/kg/d) mixed in a high-fat diet for 20 wk, then discontinued for 3 wk. Plasma BUN, plasma creatinine, and blood ¹⁸F-FDG levels were sequentially measured at each designated time point for the high-dose group (**•**), moderate-dose group (**•**), low-dose group (**•**), and control group (**•**) (n = 5-10/time point). *, Weeks after treatment cessation. In all the telmisartan-treated groups, BUN, creatinine, and ¹⁸F-FDG levels increased in the first 2 wk of the treatment and then remained the same thereafter. After the 3-wk treatment cessation, all of the parameters returned to the baseline levels.